Christopher Schott
JPMorgan Chase & Co, Analysis Division
Good afternoon, everyone. I am Chris Schott at JPMorgan, and it is my pleasure to be internet hosting this hearth dialogue with Dave Ricks, Chairman and CEO of Eli Lilly. At all times a spotlight of the convention for me. Dave, Joyful New Yr. I do know we’ll have some preliminary fast presentation, and we’ll bounce into the Q&A from there. So I am going to flip it over to Dave.
David Ricks
Chairman & CEO
Thanks, Chris. Nice. Thanks, everybody, for being right here to take heed to us, and joyful New Yr to everybody. It is an vital 12 months for Lilly. It is our a hundred and fiftieth 12 months in existence, which I feel makes us probably the most helpful outdated firm in America.
Sure. So along with celebrating that, we’ve lots to look ahead to this 12 months. I feel final 12 months at this convention, we have been coming off a 12 months the place we actually type of had our first full 12 months of weight problems launch with tirzepatide, and there have been plenty of unknowns and plenty of uncertainties. And I feel we exit that 12 months and enter ’26 with much more recognized and much more certainty. From a portfolio perspective, in fact, tirzepatide is an unbelievable molecule that is altering the lives of thousands and thousands of individuals all over the world.
However we have been working exhausting on follow-on pipeline merchandise. And within the 12 months, I feel we noticed Part III knowledge on the total program for orforglipron, our oral GLP-1, which I am positive we’ll discuss within the Q&A in addition to the primary set of information on
